Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 3 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Superinvestors holding NKTR, Q2 2026
No superinvestor reported holding NKTR in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of NKTR each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q3 2022
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital
Q2 2022
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−32.9%)
Q1 2022
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−17.7%)
Q4 2021
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−0.3%)
- Sold out
- Duquesne Family Office
Q3 2021
2 superinvestors holding at quarter end
- Added
- Maverick Capital (+1.3%)
Q2 2021
2 superinvestors holding at quarter end
- Reduced
- Maverick Capital (−1.7%)